The incidence and determinants of hepatic decompensation have been incompletely examined among patients coinfected with HIV and hepatitis C virus (HCV) in the antiretroviral therapy (ART) era, and few studies have compared outcome rates with those of patients with chronic HCV alone.
C o-infection with chronic hepatitis C virus (HCV) occurs in 10% to 30% of HIV-infected patients (1) (2) (3) (4) . The course of chronic HCV is accelerated in patients coinfected with HIV, with more rapid progression of liver fibrosis than in HCV-monoinfected patients (5-7). Consequently, HCV-related liver complications, particularly hepatic decompensation (defined by the presence of ascites, spontaneous bacterial peritonitis, variceal hemorrhage, or hepatic encephalopathy [8] ), have emerged as important causes of illness in co-infected patients (9, 10) .
Despite the importance of HCV-related end-stage liver disease, few longitudinal studies have evaluated the incidence and determinants of hepatic decompensation among patients co-infected with HIV and HCV during the antiretroviral therapy (ART) era. Previous studies suggest that ART slows progression of HCV-associated liver fibrosis, possibly by reducing HIV-related inflammation and immune dysfunction and inhibiting the ability of HIV to directly infect hepatocytes (10 -13) . However, whether rates of hepatic decompensation and other severe liver events (for example, hepatocellular carcinoma [HCC] or liver-related death) in co-infected patients receiving ART are similar to those in HCV-monoinfected patients remains unclear. Furthermore, the determinants of hepatic decompensation among co-infected patients receiving ART are unknown. Determination of these factors could help define the mechanisms of decompensation in co-infected patients and could suggest interventions to reduce the risk for end-stage liver disease in this population.
We first compared the incidence of hepatic decompensation between antiretroviral-treated patients co-infected with HIV and HCV and HCV-monoinfected patients. We hypothesized that rates of decompensation would remain higher in co-infected patients despite ART. We then evaluated host and viral factors associated with decompensation among co-infected patients.
METHODS

Study Design and Data Source
We conducted a retrospective cohort study among antiretroviral-treated patients co-infected with HIV and HCV and HCV-monoinfected patients in the VACS-VC (Veterans Aging Cohort Study Virtual Cohort) between 1 January 1997 and 30 September 2010 (14) . The VACS-VC consists of electronic medical record data from HIV-infected patients receiving care at Veterans Affairs (VA) medical facilities across the United States. Each HIVinfected patient is matched on age, sex, race/ethnicity, and site to 2 HIV-uninfected persons. Data include hospital and outpatient diagnoses (recorded using International Classification of Diseases, Ninth Revision [ICD-9], codes), procedures (recorded using CPT [Current Procedural Terminology] codes), laboratory results, and pharmacy data. Clinically confirmed cancer diagnoses are available from the VA Central Cancer Registry. Deaths are identified from the VA Vital Status file, which uses data from the Social Security Death Master File, Medicare Vital Status Files, and VA Beneficiary Identification and Records Locator Subsystem. For patients who died, principal cause of death can be determined by linkage with the National Death Index (15) . In addition, U.S. Medicare and Medicaid claims data are available for veterans also enrolled in these programs and have been merged with VACS-VC data.
Study Patients
Co-infected patients were included if they had detectable HCV RNA, had recently initiated ART (defined as use of Ն3 antiretrovirals from 2 classes [16] or Ն3 nucleoside analogues [a previously accepted ART regimen] [17] ) within the VA system, had an HIV RNA level greater than 500 copies/mL within 180 days before starting ART (to identify those who newly initiated ART [18] ), and had been observed for at least 12 months in the VACS-VC after starting ART. Monoinfected patients had detectable HCV RNA, no recorded HIV ICD-9 diagnosis or antiretroviral prescriptions, and at least 12 months of observation in the VACS-VC. Patients were excluded if, during the baseline period (defined in the Statistical Analysis section), they had hepatic decompensation, HCC, or liver transplantation or received interferon-based HCV therapy (because treatment reduces the risk for hepatic decompensation [19, 20] ).
Study Outcomes
The primary outcome was incident hepatic decompensation, which was defined by 1 ICD-9 diagnosis of ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage at hospital discharge or 2 such outpatient diagnoses in the VACS-VC (Supplement 1, available at www .annals.org). A prior study validated this determination, with 91% of events confirmed by medical records (21) . The requirement of 2 outpatient diagnoses aimed to exclude events that were suspected but not subsequently confirmed at follow-up visits. On the basis of the results of the prior validation study (21), we did not include ICD-9 diagnoses for hepatic encephalopathy and jaundice, which could indicate decompensation, because these diagnoses frequently were linked to unrelated conditions (for example, narcotic overuse, stroke recorded as encephalopathy, or biliary obstruction or atazanavir-associated hyperbilirubinemia recorded as jaundice). Date of decompensation was defined as the hospital discharge date (if identified by hospital diagnosis) or initial outpatient diagnosis date (if identified by outpatient diagnosis).
Secondary outcomes included incident hepatic decompensation (determined by the aforementioned ICD-9 -based definition) within the VACS-VC, Medicare, or Medicaid data (to capture outcomes occurring at non-VA hospitals that did not result in transfer to a VA facility; this outcome was secondary because non-VA events have not been validated); HCC; and severe liver events, a composite outcome of hepatic decompensation within the VACS-VC, HCC, or liver-related death. Hepatocellular carcinoma was determined using the VA Central Cancer Registry, which confirmed diagnoses by histologic or cytologic evaluation or consistent radiography. We classified deaths as liverrelated if the underlying cause from the National Death Index was recorded as hepatic decompensation, liver cancer, alcoholic liver disease, viral hepatitis, or nonalcoholic liver disease (Supplement 1) (15) .
Context
Patients with HIV are often co-infected with hepatitis C virus (HCV). Whether treatment of HIV with antiretroviral therapy (ART) can improve HCV outcomes is a topic of interest.
Contribution
In a Veterans Affairs study, patients co-infected with HIV and HCV who had HIV RNA levels less than 1000 copies/mL had a lower rate of hepatic decompensation than those with less HIV suppression. However, the rate was still higher than that in HCV-monoinfected patients.
Caution
Few women were studied.
Implication
Patients co-infected with HIV and HCV remain at greater risk for poor outcomes from HCV infection than HCVmonoinfected patients despite viral suppression by ART.
-The Editors
Original Research Hepatic Decompensation in Patients With HIV and Hepatitis C Virus
Data Collection
Baseline data ( Table 1) included age, sex, race/ ethnicity, VA center patient volume, body mass index (BMI), diabetes mellitus, alcohol dependence or abuse, injection or noninjection drug use, hepatitis B surface antigen status, HCV genotype, HCV RNA level, pre-ART CD4 cell count, pre-ART plasma HIV RNA level, and baseline antiretroviral regimen. Diabetes was defined as a random glucose level of at least 200 mg/dL or antidiabetic medication use (22, 23). Alcohol dependence or abuse (24) and injection or noninjection drug use (24, 25) were defined by previously validated ICD-9 diagnoses (Supplement 1). Baseline serum creatinine, hemoglobin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels and platelet count were collected from dates closest to but before the start of follow-up. Baseline FIB-4 score, a noninvasive measure of advanced hepatic fibrosis, was determined as follows:
] (26). Because liver fibrosis can progress by 1 stage as early as within 4 years for antiretroviral-treated patients co-infected with HIV and HCV (7) and within 5 years for HCV-monoinfected persons (27), we determined baseline FIB-4 scores by using ALT levels, AST levels, and platelet counts within a 2-year period around the start of followup. Scores less than 1.45 indicate no or minimal fibrosis, and scores greater than 3.25 indicate advanced hepatic fibrosis or cirrhosis in co-infected (26) and HCVmonoinfected patients (28). Longitudinal data included hepatitis B surface antigen status, plasma HIV RNA level, diabetes, and liver transplantation (determined by diagnosis and procedural codes) (Supplement 1).
Statistical Analysis
The 12 months before the start of follow-up represented the baseline period for both cohorts. Follow-up began 12 months after ART initiation for co-infected patients and after 12 months in the VACS-VC for monoinfected patients. The rationale for defining the baseline period as the first year of receipt of ART for coinfected patients was that many of these patients initially entered care at the time of ART initiation, which was shortly after their HIV diagnosis. Follow-up continued until a study end point, death, initiation of HCV therapy, or the last visit before 30 September 2010, whichever came first.
For descriptive purposes, we estimated incidence rates (events per 1000 person-years) of end points with 95% CIs, standardized by the age and race/ethnicity distribution of co-infected patients (29) . We then used Cox models to estimate adjusted hazard ratios (HRs) for outcomes in coinfected compared with monoinfected patients (30) . We controlled for all available clinically relevant variables in Table 1 . The proportionality of hazards was evaluated by plots of Schoenfeld residuals (31) . In a sensitivity analysis, we addressed the potential for informative censoring by using inverse probability of censoring weights and Cox regression (Supplement 2, available at www.annals.org) (32) .
Because mortality rates were higher for co-infected than for monoinfected patients and because death could be a competing risk for decompensation, we determined HRs for decompensation that accounted for death as a competing risk (33) . We estimated the incidence of decompensation for both cohorts, standardized to the characteristics of patients in the overall sample based on the covariates in the Cox model ( Table 2 ) and assuming that death was a competing risk.
We also performed 3 subgroup analyses. First, because co-infected patients may have had varying antiretroviral adherence during follow-up or might have interrupted or discontinued ART, thus leading to virologic failure, we compared decompensation rates in the monoinfected cohort with those in subgroups of co-infected patients stratified by HIV RNA level during follow-up (Ͻ1000 copies/mL on all results during follow-up vs. Ն1000 copies/mL on any result during follow-up). This threshold was chosen because intermittent low-level HIV viremia less than 1000 copies/mL may occur among patients receiving ART and does not necessarily indicate HIV virologic failure (34) . In a sensitivity analysis, we compared decompensation rates in the smaller subgroup of co-infected patients who maintained HIV RNA levels less than 400 copies/mL throughout follow-up (n ϭ 386) compared with monoinfected patients. Second, we compared decompensation ART ϭ antiretroviral therapy; HCV ϭ hepatitis C virus; HR ϭ hazard ratio. * HRs were adjusted for age, race, diabetes mellitus, body mass index, history of alcohol dependence/abuse, history of injection/noninjection drug use, and Veterans Affairs center patient volume. The proportion of HCV-monoinfected patients who had hemoglobin and hepatitis B surface antigen measured during the baseline period was small. As a result, these variables were not included in multivariable models comparing incidence rates of hepatic decompensation between antiretroviral-treated patients co-infected with HIV and HCV and HCV-monoinfected patients. † Patients included in the subgroup of antiretroviral-treated patients co-infected with HIV and HCV for specified analysis. Original Research Hepatic Decompensation in Patients With HIV and Hepatitis C Virus rates in the monoinfected cohort with those in co-infected patients stratified by pre-ART CD4 count (Ͻ0.200, 0.200 to 0.349, 0.350 to 0.499, and Ն0.500 ϫ 10 9 cells/L). Third, we evaluated the risk for decompensation between co-infected and monoinfected patients at the same baseline stage of liver fibrosis. This analysis focused on patients with no or minimal hepatic fibrosis (FIB-4 score Ͻ1.45) to fully evaluate the association between co-infection and decompensation.
Among co-infected patients, we used Cox and competing risk regression analyses to estimate HRs for decompensation for risk factors of interest. Hypothesized risk factors included baseline advanced hepatic fibrosis (FIB-4 score Ͼ3.25); baseline obesity (BMI Ն30 kg/m 2 ); baseline severe anemia (hemoglobin level Ͻ100 g/L); diabetes mellitus; active hepatitis B infection; nonblack race; pre-ART CD4 cell count; and HIV viremia copy-years, defined as the log copies of plasma HIV RNA per milliliter over time, which is a measure of cumulative plasma HIV burden (35) . We estimated viremia copy-years by the cumulative annual HIV viral load based on the median value of each year of follow-up. Details are presented in Supplement 3 (available at www.annals.org). Diabetes, hepatitis B, and HIV viremia copy-years were evaluated as time-varying covariates.
In a subgroup analysis among 3314 (77.4%) coinfected patients with baseline HCV RNA results reported in international units per milliliter, we evaluated the association between high baseline HCV RNA level (Ն400 000 IU/mL) and decompensation. If multiple baseline HCV RNA loads were available, the highest result was analyzed.
We performed a simulation-based sensitivity analysis to examine the effect of unmeasured confounders on the HR for decompensation between co-infected and monoinfected patients (36) . Details appear in Supplement 4 (available at www.annals.org).
We used multiple imputation to address the potential bias of missing data by means of 10 imputations using all variables in Table 1 and outcomes (37) . We combined results across the 10 data sets to arrive at CIs that accounted for variances within and across data sets (38) . Data were analyzed using SAS, version 9.2 (SAS Institute, Cary, North Carolina), and Stata 12.1 (StataCorp, College Station, Texas).
Regulatory Approvals
This study was approved by the Institutional Review Boards of the University of Pennsylvania and Philadelphia VA Medical Center.
Role of the Funding Source
This study was funded by the National Institutes of Health. The funding source had no role in data collection, analysis, or interpretation.
RESULTS
Patient Characteristics
Between 1997 and 2010, a total of 10 359 patients (4280 antiretroviral-treated patients co-infected with HIV and HCV and 6079 HCV-monoinfected patients) met our inclusion criteria (Figure 1) . Absence of HCV RNA assessment was the most common reason for exclusion from both cohorts. There were no clinically relevant differences in the characteristics between included patients ( Table 1) and those excluded due to absence of HCV RNA assessment in either cohort. Table 1 summarizes the baseline cohort characteristics. Co-infected and monoinfected patients were similar in age, race/ethnicity, diabetes, history of alcohol dependence or abuse, and history of injection or noninjection drug use. Most patients in both cohorts were infected with HCV genotype 1. Co-infected patients more commonly had a high HCV RNA level. Follow-up was shorter for coinfected than monoinfected patients (6.8 vs. 9.9 years; P Ͻ 0.001). During follow-up, 330 (7.7%) co-infected and 505 (8.3%) monoinfected patients initiated HCV therapy and were censored.
Baseline ART regimens prescribed to co-infected patients reflected the antiretroviral drugs used at the time of entry into the VACS-VC ( Table 1) . A relatively small number (162 [3.8%]) was prescribed a combination of abacavir, lamivudine, and zidovudine as the baseline regimen. Among the 241 co-infected patients who were positive for hepatitis B surface antigen, 207 (85.9%) received lamivudine alone, tenofovir plus emtricitabine, or tenofovir plus lamivudine as part of their baseline regimen. Co-infected patients had a median of 2.8 HIV RNA results (interquartile range [IQR], 1.8 to 3.8 results) measured each year during follow-up to assess HIV virologic response.
Hepatic Decompensation
Hepatic decompensation occurred more frequently in antiretroviral-treated co-infected patients (271 [ . Hazard ratios that were adjusted for informative censoring differed little (data not shown). The standardized cumulative incidence of decompensation was higher among co-infected than monoinfected patients at 10 years (7.4% vs. 4.8%; P Ͻ 0.001) (Figure 2  [top] ).
In subgroup analyses, rates of decompensation remained higher in co-infected patients who maintained HIV RNA levels less than 1000 copies/mL throughout follow-up compared with monoinfected patients ( Table 2 and Figure 2 [middle]). Similar results were observed when co-infected patients with HIV RNA levels less than 400 copies/mL throughout follow-up were compared with HCV-monoinfected patients (data not shown). Across strata of pre-ART CD4 cell count, the HR for decompensation was highest for co-infected patients with a pre-ART CD4 count less than 0.200 ϫ 10 9 cells/L compared with monoinfected persons (Table 2 and Figure 2 [bottom]). Among those with a baseline FIB-4 score less than 1.45, the risk for decompensation remained higher in co-infected than monoinfected patients (adjusted HR, 1.98 [CI, 1.23 to 3.18]).
Hepatocellular Carcinoma
The proportions of co-infected and monoinfected patients who developed HCC were similar (74 [1.7%] vs. 100 [1.6%]; P ϭ 0.74). After adjustment for age, race, diabetes, BMI, alcohol abuse, injection or noninjection drug use, and VA center patient volume, rates of HCC were higher for co-infected patients (HR, 1.60 [CI, 1.16 to 2.21]). This association did not remain significant in a competing risk analysis ( Table 2) . Median survival after HCC diagnosis was shorter for co-infected patients (8.7 months [IQR, 2.3 to 27.3 months] vs. 14.2 months [IQR, 3.8 to 101.8 months]), but this difference was not significant (P ϭ 0.22). There were no important differences in age at diagnosis, race, BMI, diabetes, or alcohol abuse between co-infected and monoinfected patients with HCC (Appendix Table 1 , available at www.annals.org).
Severe Liver Events and Death
Severe liver events were more common in co-infected than monoinfected patients (373 [8.7%] vs. 433 [7.1%] ; P ϭ 0.003), and co-infected patients had a higher risk for this end point ( Table 2 , available at www.annals.org).
Factors Associated With Decompensation Among Co-infected Patients
Baseline advanced hepatic fibrosis, baseline hemoglobin level less than 100 g/L, diabetes, and nonblack race were risk factors for decompensation ( Table 3) . The hazard for HIV viremia copy-years greater than 6 log copyyears/mL was approximately twice that of the reference group (Ͻ2 log copy-years/mL), but these results did not approach statistical significance.
The incidence of decompensation was similar between co-infected patients with baseline HCV RNA levels of 400 000 IU/mL or greater and those with levels less than 400 000 IU/mL (5 
DISCUSSION
In this study, antiretroviral-treated patients co-infected with HIV and HCV had higher rates of hepatic decompensation and severe liver events than HCV-monoinfected patients. Co-infected patients who maintained HIV RNA levels less than 1000 copies/mL or less than 400 copies/mL over the median 6.8 years of follow-up still had higher rates of decompensation, suggesting that HIV viral suppression below these thresholds with ART is not sufficient to reduce rates of end-stage liver disease to those of HCVmonoinfected patients. Furthermore, among patients with minimal or no fibrosis at baseline, the risk for decompensation remained higher for co-infected patients. Rates of decompensation were highest for patients with pre-ART CD4 counts less than 0.200 ϫ 10 9 cells/L compared with monoinfected patients. Finally, among co-infected patients receiving ART, baseline advanced liver fibrosis, severe anemia, diabetes, and nonblack race were each associated with higher rates of decompensation.
Our analyses examining the risk for decompensation between co-infected and monoinfected patients did not control for baseline stage of hepatic fibrosis because the development of liver fibrosis is in the causal pathway to hepatic decompensation. Thus, controlling for baseline hepatic fibrosis could adjust away an association between treated HIV and decompensated cirrhosis. We conducted a secondary analysis restricted to patients with minimal or no liver fibrosis (FIB-4 score Ͻ1.45) at baseline. Antiretroviral-treated co-infected patients continued to have an increased risk for hepatic decompensation compared with monoinfected patients. 9 cells/L were collapsed into a single plot because these hazard ratios were indistinguishable (see Table 2 ).
The mechanisms for the higher rates of hepatic decompensation in co-infected patients receiving ART remain unclear. HIV-related immune dysregulation, HIVmediated depletion of CD4 cells in the gastrointestinal tract with resultant microbial translocation, oxidative stress related to co-infection with HIV and HCV, and HIVinduced hepatocyte apoptosis have been implicated in the pathogenesis of progressive hepatic disease in patients coinfected with HIV and HCV (13) . Other cofactors, such as hepatic steatosis and cumulative exposure to potentially hepatotoxic medications, particularly selected antiretroviral drugs (39 -41) , might also accelerate liver disease progression in co-infected patients.
We found that variceal hemorrhage was less commonly an initial presenting decompensation event among co-infected patients. A similar finding was reported in a cohort study of Spanish patients who were co-infected with HIV and HCV (42) . Prior studies have suggested that HIV infection is associated with protein C deficiency (43) (44) (45) and protein S deficiency (46) , which can promote hypercoagulability and reduce the likelihood of variceal bleeding among co-infected patients.
We found a higher rate of HCC in co-infected patients receiving ART than in HCV-monoinfected patients, but this difference was not statistically significant after adjustment for competing risk. A prior cohort study conducted between 1992 and 2000 showed that co-infection with HIV and HCV was not associated with an increased risk for HCC compared with HCV monoinfection in either the pre-ART or ART eras (47) . As life expectancy continues to increase among patients co-infected with HIV and HCV, clinically important differences in rates of HCC may become apparent in the future.
We identified several important factors associated with hepatic decompensation in co-infected patients. Diabetes is associated with hepatic steatosis (48) , which could promote hepatic inflammation and accelerate liver fibrosis progression (49) . Diabetes might also induce hepatic fibrosis independent of steatosis via stimulation of hepatic stellate cells by insulin (50, 51) . Severe anemia might be a marker of advanced HCV-associated liver disease, potentially indicating blood loss from variceal bleeding. Alternatively, anemia may be a marker for systemic inflammation (52), which may promote hepatic fibrosis. Nonblack HCVinfected patients have been reported to have stronger HCV-specific immunity than black patients (53), which could result in increased immune-mediated hepatic inflammation and accelerated liver fibrosis progression.
Our results suggest that the highest level of HIV viremia copy-years (Ͼ6 log copy-years/mL of HIV RNA) might increase the risk for hepatic decompensation. However, plasma viral loads were measured infrequently in many patients, with variable numbers and timing. Given our additional finding of a higher risk for decompensation in co-infected patients with pre-ART CD4 counts less than 0.200 ϫ 10 9 cells/L than in monoinfected patients, suppression of HIV while receiving ART and resultant immune reconstitution should remain a key goal for patients co-infected with HIV and HCV to possibly reduce the risk for end-stage liver disease.
Neither hepatitis B infection nor HCV RNA level was associated with hepatic decompensation among co-infected patients. Most co-infected patients (85.9%) who were positive for hepatitis B surface antigen received hepatitis Bactive ART, and this might have mitigated the association between hepatitis B and decompensation. Future analyses should test this hypothesis. Moreover, although several studies in HCV-monoinfected patients have suggested that higher HCV RNA levels are associated with more advanced liver fibrosis (54 -56) or death from end-stage liver disease (57), most have found no association between Our results have important clinical implications. The finding that antiretroviral-treated co-infected patients who maintained an HIV RNA level less than 1000 copies/mL had lower rates of hepatic decompensation than those who did not achieve HIV suppression below this level suggests that suppression of HIV RNA with ART is an important factor in slowing progression of HCV-related liver fibrosis. This observation supports current management guidelines that recommend initiation of ART among patients coinfected with HIV and HCV, regardless of CD4 cell count (16, 63) . Furthermore, the increased rate of hepatic decompensation among co-infected patients should prompt earlier consideration of initiation of HCV therapy to try to reduce the risk for liver complications (19, 20) . Recent clinical trials evaluating boceprevir-and telaprevir-based antiviral therapy among patients co-infected with HIV and HCV genotype 1 show sustained HCV virologic response rates that are similar to those of HCV-monoinfected patients (64, 65) . Providers might also address modifiable risk factors, such as diabetes, to try to decrease the risk for end-stage liver disease.
This study has several potential limitations. First, decompensation outcomes could have been misclassified. However, hepatic decompensation was identified using a validated definition (21) . We might have underestimated the number of decompensation events because our definition did not include hepatic encephalopathy; however, the negative predictive value of our validated definition exceeded 99% (21) . In addition, the incidence rates of decompensation among co-infected (9.5 per 1000 personyears) and monoinfected (5.7 per 1000 person-years) patients in this study were similar to those reported in other cohorts of co-infected (11.6 per 1000 person-years [10] ) and monoinfected (3.4 per 1000 person-years [62]) patients. The potential exists for differential ascertainment of outcomes if patients in one of the cohorts more frequently presented to non-VA hospitals for care. To address this issue, we evaluated incident decompensation events within the VA system and in the U.S. Medicare and Medicaid programs, as well as liver-related deaths within a composite severe liver event outcome. The association between antiretroviral-treated co-infection and these composite end points remained in both analyses. Second, residual confounding by unmeasured factors (for example, duration of HCV infection or alcohol dependence or drug use during follow-up) is possible. However, sensitivity analyses (Supplement 4) suggested that our results were robust to the potential bias from unobserved confounders. Third, the median follow-up among the monoinfected patients was longer than that for the co-infected patients. However, both cohorts included patients in all age groups and produced risk sets of adequate size for all combinations of decompensation risk factors across age groups; therefore, they covered the spectrum of risk among young, middleaged, and older HCV-infected patients. Finally, our study sample predominantly comprised male U.S. veterans, so results may not be generalizable to women. Because progression of HCV-related liver fibrosis differs by sex (60, 66, 67) , future epidemiologic analyses should evaluate endstage liver disease events among women co-infected with HIV and HCV and HCV-monoinfected women.
This study has several strengths. It is, to our knowledge, the largest study to evaluate liver-related events among antiretroviral-treated co-infected patients and to compare outcomes with those of HCV-monoinfected persons. It had a long duration of follow-up, evaluated validated end points (21) , accounted for time-varying covariates, and identified decompensations and liver-related deaths outside the VA system, ensuring that few outcomes were missed.
In conclusion, we found that patients co-infected with HIV and HCV who were receiving ART had higher rates of hepatic decompensation and severe liver events than HCV-monoinfected patients. Among co-infected patients receiving ART, baseline advanced liver fibrosis, severe anemia, diabetes, and nonblack race were associated with higher rates of decompensation. Clinicians should address modifiable risk factors and consider treatment of HCV infection in co-infected patients to reduce rates of hepatic decompensation.
